API Dabrafenib

Dabrafenib More Info

Dabrafenib is an oral small-molecule targeted anticancer drug that acts as a selective inhibitor of BRAF serine/threonine kinase. It is primarily used for the treatment of cancers driven by specific BRAF gene mutations, with the most common being the BRAF V600E and BRAF V600K mutations.

Core Mechanism of Action

The BRAF protein is a key component of the RAS/RAF/MEK/ERK signaling pathway, which regulates cell proliferation and survival. Mutant BRAF (e.g., V600E) leads to constitutive activation of this pathway, causing uncontrolled cell growth and tumorigenesis.

Dabrafenib binds to the ATP-binding site of mutant BRAF, blocking its kinase activity and inhibiting the downstream signaling cascade. This effectively suppresses the proliferation of cancer cells harboring BRAF mutations and induces their apoptosis.

Indications

Dabrafenib is approved for clinical use in multiple regions, including the US, EU, and China, for the following indications:

Unresectable or metastatic melanoma: Monotherapy or in combination with trametinib (a MEK inhibitor) for patients with BRAF V600E/K-mutant melanoma. Combination therapy significantly improves progression-free survival (PFS) and overall survival (OS) compared to monotherapy.

Advanced non-small cell lung cancer (NSCLC): Combined with trametinib for patients with metastatic NSCLC harboring BRAF V600E mutations, who have previously received no systemic treatment for advanced disease.

Anaplastic thyroid cancer (ATC): Combined with trametinib for locally advanced, unresectable, or metastatic ATC with BRAF V600E mutations.

Key Specifications & Administration

Dosage form: Film-coated tablets, available in strengths of 50 mg and 75 mg.

Administration: Oral administration, usually once or twice daily, with or without food. The specific dose depends on the indication and combination regimen.

Contraindications: Hypersensitivity to dabrafenib or any excipients in the formulation.

Adverse Reactions

Common adverse reactions associated with dabrafenib (especially in combination with trametinib) include:

Cutaneous reactions: Hyperkeratosis, papilloma, rash, photosensitivity.

Gastrointestinal disorders: Nausea, diarrhea, vomiting.

Other: Fever, fatigue, arthralgia, hypertension.

Serious adverse events may include cardiomyopathy, hemorrhage, and severe skin reactions, which require close monitoring during treatment.

Market Status

Dabrafenib was originally developed by GlaxoSmithKline (GSK) and later transferred to Novartis. It has been approved in major global markets, with generic versions gradually entering the market in some regions, expanding its accessibility for patients.

Note for Business Scenarios

For pharmaceutical raw material suppliers, dabrafenib’s active pharmaceutical ingredient (API) requires strict compliance with quality standards such as USP, EP, or CP, given its status as a prescription anticancer drug. The supply chain is subject to rigorous regulatory oversight related to drug registration and production quality management.